AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AIMOVIG® (erenumab-aooe)	Neuroscience	Pediatric Migraine	Monoclonal Antibody	3
	DESCRIPTION Aimovig is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients. **ADDITIONAL INFORMATION** Aimovig is developed in collaboration with Novartis.			
AMJEVITA® (adalimumab-atto)	Inflammation	Interchangeability	Monoclonal Antibody	3
	DESCRIPTION AMJEVITA (adalimumab-atto) is a biosimilar to HUMIRA® (adalimumab), which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha. **ADDITIONAL INFORMATION** HUMIRA is a registered trademark of AbbVie Biotechnology Ltd. AMJEVITA is a registered trademark of Amgen Inc.			
BEMARITUZUMAB	Hematology/Oncology	Gastric and Gastroesophageal Junction (GEJ) Cancers	Monoclonal Antibody	3
	DESCRIPTION Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric and Gastroesophageal Junction (GEJ) Cancers. **ADDITIONAL INFORMATION** In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for bemarituzumab. **ADDITIONAL CLINICAL STUDIES** Bemarituzumab is also in Phase 1 and Phase 2 development for the treatment of advanced Gastric and Gastroesophageal cancers in combination with other therapies.			
	Hematology/Oncology	Other Tumors	Monoclonal Antibody	2
	DESCRIPTION Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced solid tumors other than advanced squamous non-small cell lung cancer.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
BLINCYTO® (blinatumomab)	Hematology/Oncology	Acute Lymphoblastic Leukemia	BiTE® Molecule	3
	DESCRIPTION BLINCYTO is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of newly diagnosed adults and pediatric patients with B-Cell precursor Acute Lymphoblastic Leukemia (ALL). **ADDITIONAL CLINICAL STUDIES** Blinatumomab is also in Phase 1 development being investigated for subcutaneous administration for the treatment of adults with relapsed/refractory Acute Lymphoblastic Leukemia (ALL).			
	Inflammation	Systemic Lupus Erythematosus with Nephritis	BiTE® Molecule	2
	DESCRIPTION Blinatumomab is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated as treatment for patients with systemic lupus erythematosus with nephritis.			
DAZODALIBEP	Rare Disease	Sjögren's Disease	Fusion Protein	3
	DESCRIPTION Dazodalibep is a fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. It is being investigated for the treatment of Sjögren's disease.			
EVENITY® (romosozumab-aqqg)	Bone	Male Osteoporosis	Monoclonal Antibody	3
	DESCRIPTION EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of male osteoporosis. **ADDITIONAL INFORMATION** EVENITY is being developed in collaboration with UCB.			
	Bone	Pediatric Osteogenesis Imperfecta	Monoclonal Antibody	3
	DESCRIPTION EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients. **ADDITIONAL CLINICAL STUDIES** EVENITY is being developed in collaboration with UCB.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
IMDELLTRA® (tarlatamab-dlle)	Hematology/Oncology	Small Cell Lung Cancer	BiTE® Molecule	3
	DESCRIPTION IMDELLTRA is an anti-delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of small cell lung cancer. **ADDITIONAL CLINICAL STUDIES** IMDELLTRA is also being investigated in combination with other therapies. Tarlatamab is also being investigated in Phase 1 for subcutaneous administration and in Phase 2 for alternate dosing regimens for the treatment of small cell lung cancer.			
	Hematology/Oncology	Neuroendocrine Prostate Cancer	BiTE® Molecule	1
	DESCRIPTION IMDELLTRA is an anti-delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of DLL3+ neuroendocrine prostate cancer.			
LUMAKRAS® (sotorasib)	Hematology/Oncology	Advanced Colorectal Cancer	Small Molecule	3
	DESCRIPTION LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of previously treated advanced KRAS G12C-mutated colorectal cancer in combination with another therapy. **ADDITIONAL CLINICAL STUDIES** LUMAKRAS is also being investigated in newly diagnosed advanced KRAS G12C-mutated CRC in combination with other therapies.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
LUMAKRAS® (sotorasib)	Hematology/Oncology	Non-Small Cell Lung Cancer	Small Molecule	3
	DESCRIPTION LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of previously treated advanced KRAS G12C-mutated non-small cell lung cancer. **ADDITIONAL CLINICAL STUDIES** LUMAKRAS is also being investigated in newly diagnosed advanced KRAS G12C-mutated NSCLC in combination with other therapies.			
MARIDEBART CAFRAGLUTIDE (MariTide, formerly AMG 133)	Cardiometabolic	Obesity	Peptide-Antibody Conjugate	3
	DESCRIPTION Maridebart cafraglutide (MariTide, formerly AMG 133) is a peptide-antibody conjugate that activates the glucagon-like peptide 1 (GLP-1) receptor and antagonizes the gastric inhibitory polypeptide receptor (GIPR). It is being investigated for the treatment of obesity.			
	Diabetes	Type 2 Diabetes	Peptide-Antibody Conjugate	2
	DESCRIPTION Maridebart cafraglutide (MariTide, formerly AMG 133) is a peptide-antibody conjugate that activates the glucagon-like peptide 1 (GLP-1) receptor and antagonizes the gastric inhibitory polypeptide receptor (GIPR). It is being investigated for the treatment of Type 2 diabetes.			
NPLATE® (romiplostim)	Hematology/Oncology	Chemotherapy-Induced Thrombocytopenia	Peptibody	3
	DESCRIPTION Nplate is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT).			
OLPASIRAN (formerly AMG 890)	Cardiometabolic	Cardiovascular Disease	siRNA	3
	DESCRIPTION Olpasiran (formerly AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
OTEZLA® (apremilast)	Inflammation	Juvenile Psoriatic Arthritis	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients.			
	Inflammation	Pediatric Behcet's Disease	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet's disease in pediatric patients.			
PARSABIV® (etelcalcetide)	Nephrology	Pediatric Secondary Hyperparathyroidism	Peptide	3
	DESCRIPTION Parsabiv is a calcium-sensing receptor agonist. It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis.			
PROLIA® (denosumab)	Bone	Pediatric Glucocorticoid-Induced Osteoporosis	Monoclonal Antibody	3
	DESCRIPTION Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients.			
REPATHA® (evolocumab)	Cardiometabolic	Hypercholesterolemia	Monoclonal Antibody	3
	DESCRIPTION Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated in patients at high cardiovascular risk without a prior myocardial infarction or stroke.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
ROCATINLIMAB (formerly AMG 451 / KHK4083)	Inflammation	Atopic Dermatitis	Monoclonal Antibody	3
	DESCRIPTION Rocatinlimab (formerly AMG 451 / KHK4083) is a T-cell rebalancing monoclonal antibody that inhibits and reduces pathogenic T-cells by targeting the OX40 receptor. It is being investigated for the treatment of moderate-to-severe atopic dermatitis. **ADDITIONAL INFORMATION** Rocatinlimab is being developed in collaboration with Kyowa Kirin Co., Ltd.			
	Inflammation	Prurigo Nodularis	Monoclonal Antibody	3
	DESCRIPTION Rocatinlimab (formerly AMG 451 / KHK4083) is a T-cell rebalancing monoclonal antibody that inhibits and reduces pathogenic T-cells by targeting the OX40 receptor. It is being investigated for the treatment of prurigo nodularis. **ADDITIONAL INFORMATION** Rocatinlimab is being developed in collaboration with Kyowa Kirin Co., Ltd.			
	Inflammation	Asthma	Monoclonal Antibody	2
	DESCRIPTION Rocatinlimab (formerly AMG 451 / KHK4083) is a T-cell rebalancing monoclonal antibody that inhibits and reduces pathogenic T-cells by targeting the OX40 receptor. It is being investigated for the treatment of moderate-to-severe asthma. **ADDITIONAL INFORMATION** Rocatinlimab is being developed in collaboration with Kyowa Kirin Co., Ltd.			
TAVNEOS® (avacopan)	Rare Disease	Pediatric Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	Small Molecule	3
	DESCRIPTION TAVNEOS is a complement 5a receptor 1 (C5aR1) antagonist that inhibits the effects of C5a.It is being investigated for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)) in pediatric patients.			
TEPEZZA® (teprotumumab-trbw)	Rare Disease	Thyroid Eye Disease	Monoclonal Antibody	3
	DESCRIPTION Teprotumumab is a monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R). It is being investigated for subcutaneous administration for the treatment of thyroid eye disease.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN



MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
TEZSPIRE® (tezepelumab-ekko)	Inflammation	Asthma	Monoclonal Antibody	3
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the reduction of oral corticosteroid use in adults with oral corticosteroid dependent asthma. **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			
	Inflammation	Chronic Obstructive Pulmonary Disease	Monoclonal Antibody	3
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc. In July 2024, Amgen announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TEZSPIRE.			
	Inflammation	Chronic Rhinosinusitis with Nasal Polyps	Monoclonal Antibody	3
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
TEZSPIRE® (tezepelumab-ekko)	Inflammation	Eosinophilic Esophagitis	Monoclonal Antibody	3
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of eosinophilic esophagitis (EoE). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			
UPLIZNA® (inebilizumab-cdon)	Rare Disease	IgG4-Related Disease	Monoclonal Antibody	3
	DESCRIPTION UPLIZNA is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody that binds to the B cell-specific surface antigen CD19. It is being investigated for the prevention of flares in patients with IgG4-related disease. **ADDITIONAL INFORMATION** In September 2024, Amgen announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to UPLIZNA in the treatment of IgG4-related disease.			
	Rare Disease	Myasthenia Gravis	Monoclonal Antibody	3
	DESCRIPTION UPLIZNA is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody that binds to the B cell-specific surface antigen CD19. It is being investigated for improving outcomes in patients with myasthenia gravis.			
	Inflammation	Systemic Lupus Erythematosus with Nephritis	Monoclonal Antibody	2
	DESCRIPTION Inebilizumab is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody that binds to the B cell-specific surface antigen CD19. It is being investigated as treatment for patients with systemic lupus erythematosus with nephritis.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
XALURITAMIG (formerly AMG 509)	Hematology/Oncology	Prostate Cancer	XmAb® Antibody	3
	DESCRIPTION Xaluritamig is an anti-six transmembrane epithelial antigen of the prostate 1 (STEAP1) x anti-CD3 XmAb® bispecific T cell engager molecule. It is being investigated for the treatment of prostate cancer. **ADDITIONAL INFORMATION** XmAb is a registered trademark of Xencor, Inc. **ADDITIONAL CLINICAL STUDIES** Xaluritamig is also being investigated in combination with other therapies.			
ABP 206 (Investigational biosimilar to OPDIVO® (nivolumab))	Hematology/Oncology	Investigational Biosimilar	Monoclonal Antibody	3
	DESCRIPTION ABP 206 is an investigational biosimilar to OPDIVO (nivolumab), which is a monoclonal antibody that binds to the receptor protein called programmed death protein 1 (PD-1). **ADDITIONAL INFORMATION** OPDIVO is a registered trademark of Bristol-Myers Squibb Company.			
ABP 234 (Investigational biosimilar to KEYTRUDA® (pembrolizumab))	Hematology/Oncology	Investigational Biosimilar	Monoclonal Antibody	3
	DESCRIPTION ABP 234 is an investigational biosimilar to KEYTRUDA (pembrolizumab), which is a monoclonal antibody that binds to the receptor protein called programmed death protein 1 (PD-1). **ADDITIONAL INFORMATION** KEYTRUDA is a registered trademark of Merck & Co.			
ABP 692 (Investigational biosimilar to OCREVUS® (ocrelizumab))	Inflammation	Investigational Biosimilar	Monoclonal Antibody	3
	DESCRIPTION ABP 692 is an investigational biosimilar to OCREVUS (ocrelizumab), which is a monoclonal antibody that binds to CD20, which is a protein found on the surface of B-cells. **ADDITIONAL INFORMATION** OCREVUS is a registered trademark of Genentech.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
DAXDILIMAB	Rare Disease	Dermatomyositis and Anti-Synthetase Inflammatory Myositis	Monoclonal Antibody	2
	DESCRIPTION Daxdilimab is a fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. It is being investigated for the treatment of dermatomyositis and anti-synthetase inflammatory myositis.			
	Rare Disease	Discoid Lupus Erythematosus	Monoclonal Antibody	2
	DESCRIPTION Daxdilimab is a fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. It is being investigated for the treatment of discoid lupus erythematosus			
KYPROLIS® **(carfilzomib)**	Hematology/Oncology	Pediatric Acute Lymphoblastic Leukemia	Small Molecule	2
	DESCRIPTION KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients.			
ORDESEKIMAB** **(formerly AMG 714 / PRV-015)**	Inflammation	Celiac Disease	Monoclonal Antibody	2
	DESCRIPTION Ordesekimab (formerly AMG 714/PRV-015) is a monoclonal antibody that inhibits the action of Interleukin-15 (IL-15). It is being investigated for the treatment of non-responsive celiac disease as an adjunct to a gluten free diet. **ADDITIONAL INFORMATION** Ordesekimab is being developed in collaboration with Provention Bio, a Sanofi company.			
AMG 104	Inflammation	Asthma	Monoclonal Antibody	2
	DESCRIPTION AMG 104 is a human anti-TSLP Fab. It is being investigated for the treatment of asthma. **ADDITIONAL INFORMATION** AMG 104 is being developed in collaboration with AstraZeneca plc.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 193	Hematology/Oncology	Non-Small Cell Lung Cancer	Small Molecule	2
	DESCRIPTION AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of non-small cell lung cancer. **ADDITIONAL CLINICAL STUDIES** AMG 193 is also in Phase 1 development for treatment of non-small cell lung cancer in combination with other therapies.			
	Hematology/Oncology	Other Tumors	Small Molecule	1
	DESCRIPTION AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors other than non-small cell lung cancer. **ADDITIONAL INFORMATION** AMG 193 is also in Phase 1 development for treatment of solid tumors in combination with other therapies.			
AMG 329 **(formerly HZN-1116)**	Rare Disease	Sjögren's Disease	Monoclonal Antibody	2
	DESCRIPTION AMG 329 is a fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. It is being investigated for the treatment of Sjögren's disease.			
AMG 305	Hematology/Oncology	Colorectal Cancer	BiTE® Molecule	1
	DESCRIPTION AMG 305 is a dual-targeting bispecific T cell engager (BiTE) molecule against P-cadherin (CDH3), mesothelin (MSLN) and CD3. It is being investigated for the treatment of solid tumors.			
AMG 355	Hematology/Oncology	Solid Tumors	Monoclonal Antibody	1
	DESCRIPTION AMG 355 is an anti-CCR8 monoclonal antibody. It is being investigated for the treatment of advanced solid tumor malignancies.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 378	Inflammation	Ulcerative Colitis	Small Molecule	1
	DESCRIPTION AMG 378 is a small molecule being investigated for the treatment of ulcerative colitis.			
AMG 513	Cardiometabolic	Obesity		1
	DESCRIPTION AMG 513 is a molecule being investigated for the treatment of obesity.			
AMG 691	Inflammation	Asthma	Monoclonal Antibody	1
	DESCRIPTION AMG 691 is a monoclonal antibody being investigated for the treatment of asthma.			
AMG 732 (formerly HZN-280)	Rare Disease	Thyroid Eye Disease	Monoclonal Antibody	1
	DESCRIPTION AMG 732 is a monoclonal antibody being investigated for the treatment of thyroid eye disease.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being out licensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.